OPR - Delayed Quote • USD ADAP Sep 2024 2.000 call (ADAP240920C00002000) Follow 0.2400 0.0000 (0.00%) At close: April 24 at 1:00 PM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for ADAP240920C00002000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: ADAP Adaptimmune (ADAP) Down on End of Collaboration With Roche Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated Roche, Adaptimmune part ways on cell therapy research Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet Adaptimmune Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024 15 Top Performing European Stocks So Far in 2024 Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know
